Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 6/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.69 |
| ▸ | LMNA | P02545 | 2/20 | 0.69 |
| ▸ | ADRB2 | P07550 | 6/20 | 0.67 |
| ▸ | ADRA2A | P08913 | 4/20 | 0.57 |
| ▸ | ADRA2C | P18825 | 4/20 | 0.57 |
| ▸ | DRD1 | P21728 | 3/20 | 0.57 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.57 |
| ▸ | DRD3 | P35462 | 3/20 | 0.57 |
| ▸ | DRD2 | P14416 | 2/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.49 |
| ▸ | TSHR | P16473 | 3/20 | 0.49 |
| ▸ | ADRB1 | P08588 | 3/20 | 0.49 |
| ▸ | ADRB3 | P13945 | 3/20 | 0.49 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9346029 | 0.92 | ALDH1A1 (0.60) | HIF1AALDH1A1CYP3A4LMNAADRB2 | |
| Hydrochloric Acid SCHEMBL9348690 | 0.91 | ADRB2 (0.61) | HIF1AALDH1A1CYP3A4LMNAADRB2 | |
| Hydrochloric Acid SCHEMBL9348676 | 0.89 | ADRB2 (0.59) | HIF1AALDH1A1CYP3A4LMNAADRB2 | |
| SCHEMBL20142113 | 0.89 | HIF1A (0.66) | HIF1AALDH1A1CYP3A4LMNAADRB2 | |
| SCHEMBL21529463 | 0.89 | HIF1A (0.66) | HIF1AALDH1A1CYP3A4LMNAADRB2 | |
| SCHEMBL23318541 | 0.89 | ADRB2 (0.57) | HIF1AALDH1A1CYP3A4LMNAADRB2 | |
| SCHEMBL23318543 | 0.89 | ADRB2 (0.57) | HIF1AALDH1A1CYP3A4LMNAADRB2 | |
| SCHEMBL20142428 | 0.89 | HIF1A (0.69) | HIF1AALDH1A1CYP3A4LMNAADRB2 | |
| Hydrochloric Acid SCHEMBL9344045 | 0.88 | ADRB2 (0.58) | HIF1AALDH1A1CYP3A4LMNAADRB2 | |
| Hydrochloric Acid SCHEMBL9344932 | 0.88 | ADRB2 (0.58) | HIF1AALDH1A1CYP3A4LMNAADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11021437-B2 | Pharmaceutical formulation for sublingual or buccal delivery of epinephrine or a pro-drug thereof | IONO PHARMA, LLC (US) | 2021-06-01 | — | — | US | claimed |
| US-20190337886-A1 | PHARMACEUTICAL FORMULATION FOR SUBLINGUAL OR BUCCAL DELIVERY OF EPINEPHRINE OR A PRO-DRUG THEREOF | lono Pharma, LLC (US) | 2019-11-07 | — | — | US | claimed |
| US-11021437-B2 | Pharmaceutical formulation for sublingual or buccal delivery of epinephrine or a pro-drug thereof | IONO PHARMA, LLC (US) | 2021-06-01 | — | — | US | disclosed |
| US-20210128511-A1 | PRODRUG COMPOSITIONS AND METHODS OF TREATMENT | AQUESTIVE THERAPEUTICS, INC. (US) | 2021-05-06 | — | — | US | disclosed |
| WO-2021087359-A1 | PRODRUG COMPOSITIONS AND METHODS OF TREATMENT | AQUESTIVE THERAPEUTICS, INC. (US) | 2021-05-06 | — | — | WO | disclosed |
| US-20190337886-A1 | PHARMACEUTICAL FORMULATION FOR SUBLINGUAL OR BUCCAL DELIVERY OF EPINEPHRINE OR A PRO-DRUG THEREOF | lono Pharma, LLC (US) | 2019-11-07 | — | — | US | disclosed |
| WO-2018089570-A1 | PHARMACEUTICAL FORMULATION FOR SUBLINGUAL OR BUCCAL DELIVERY OF EPINEPHRINE | IONO PHARMA, LLC (US) | 2018-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210128511-A1 | PRODRUG COMPOSITIONS AND METHODS OF TREATMENT | ADRA2C, ADRB3, ADRA2B | HIF1A 2267/4885ALDH1A1 559/4885CYP3A4 127/4885 |
| US-20190337886-A1 | PHARMACEUTICAL FORMULATION FOR SUBLINGUAL OR BUCCAL DELIVERY OF EPINEPHRINE OR A PRO-DRUG THEREOF | ADRB3, ADRB1, ADRB2 | HIF1A 2251/4885ALDH1A1 1112/4885CYP3A4 70/4885 |
| US-11021437-B2 | Pharmaceutical formulation for sublingual or buccal delivery of epinephrine or a pro-drug thereof | ADRB3, ADRB1, ADRB2 | HIF1A 2251/4885ALDH1A1 1112/4885CYP3A4 70/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.